secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-08-11T20:08:50+00:00
Accession:  0001193125-26-344623
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Q2 net loss widens to $19.6M; Phase 3 PAH trial advances with $50M financing
--------------------------------------------------------------------------------

- Q2 2026 net loss $19.6M ($0.11/share) vs $9.9M loss in Q2 2025; R&D spend up to $13.4M from $5.3M.
- Cash, equivalents, and marketable securities $159.0M at June 30, 2026; plus $50M gross from 25M shares sold to RA Capital in July 2026.
- FDA granted Orphan Drug Designation for IKT-001 in July 2026; Phase 3 IMPROVE-PAH approvals in 26 countries, 43 sites initiated.
- Company expects existing and new capital to fund operations through Part B topline data readout, assuming warrant exercise.
- Pre-clinical/Phase 1 data at ATS showed improved GI profile vs imatinib and 18-fold lower c-Kit inhibition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/0001193125-26-344623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526344623/d134059d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer